GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Loans Receivable

Vectus Biosystems (ASX:VBS) Loans Receivable : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Loans Receivable?

Vectus Biosystems's Loans Receivable for the quarter that ended in Dec. 2023 was A$0.00 Mil.


Vectus Biosystems Loans Receivable Historical Data

The historical data trend for Vectus Biosystems's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Loans Receivable Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Loans Receivable
Get a 7-Day Free Trial - - - - -

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vectus Biosystems Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Vectus Biosystems Loans Receivable Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines